ALK inhibitors do not increase sensitivity to radiation in EML4-ALK non-small cell lung cancer

K Fleschutz, L Walter, R Leistner… - Anticancer …, 2020 - ar.iiarjournals.org
Background/Aim: ALK inhibitors like Crizotinib, Ceritinib and Alectinib are targeted therapies
used in patients with anaplastic lymphoma kinase (ALK)-positive, advanced non-small cell …

ALK inhibitor PF02341066 (crizotinib) increases sensitivity to radiation in non–small cell lung cancer expressing EML4-ALK

Y Sun, KA Nowak, NG Zaorsky, CL Winchester… - Molecular cancer …, 2013 - AACR
Crizotinib (PF02341066) is a tyrosine kinase inhibitor of anaplastic lymphoma kinase (ALK)
that has been shown to selectively inhibit growth of cancer cells that harbor the EML4-ALK …

Synergistic effects of crizotinib and radiotherapy in experimental EML4–ALK fusion positive lung cancer

Y Dai, Q Wei, C Schwager, M Moustafa, C Zhou… - Radiotherapy and …, 2015 - Elsevier
Background and purpose Non-small cell lung cancer (NSCLC) patients with chromosomal
rearrangements of the anaplastic lymphoma kinase gene (ALK) are sensitive to the tyrosine …

Crizotinib for EML4-ALK positive lung adenocarcinoma: a hope for the advanced disease? Evaluation of Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma …

SA Antoniu - Expert Opinion on Therapeutic Targets, 2011 - Taylor & Francis
Introduction: In lung adenocarcinoma, certain mutations such as echinoderm microtubule-
associated protein-like 4-anaplastic lymphoma kinase (ALK) are associated with lower …

[HTML][HTML] Oncogene addiction and radiation oncology: effect of radiotherapy with photons and carbon ions in ALK-EML4 translocated NSCLC

Y Dai, Q Wei, C Schwager, J Hanne, C Zhou… - Radiation …, 2018 - Springer
Abstract Background Patients with Echinoderm microtubule-associated protein-like 4
(EML4)-anaplastic lymphoma kinase (ALK) positive lung cancer are sensitive to ALK-kinase …

Analysis of resistance mechanisms to ALK kinase inhibitors in ALK+ NSCLC patients.

RC Doebele, DL Aisner, AT Le, EM Berge, AB Pilling… - 2012 - ascopubs.org
7504 Background: Patients with anaplastic lymphoma kinase (ALK) gene fusions derive
significant clinical benefit from crizotinib, an ALK inhibitor; moreover, next generation ALK …

Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy

BC Liao, CC Lin, JY Shih… - Therapeutic advances in …, 2015 - journals.sagepub.com
Rearrangements in anaplastic lymphoma kinase (ALK) gene and echinoderm microtubule-
associated protein-like 4 (EML4) gene were first described in a small portion of patients with …

Overcoming resistance by ALK compound mutation (I1171S+ G1269A) after sequential treatment of multiple ALK inhibitors in non‐small cell lung cancer

K Takahashi, Y Seto, K Okada, S Uematsu… - Thoracic …, 2020 - Wiley Online Library
Background Anaplastic lymphoma kinase (ALK) fusion genes are found in 3%–5% of non‐
small cell lung cancers (NSCLCs). ALK inhibitors show a very high response rate to ALK …

ALK mutations conferring differential resistance to structurally diverse ALK inhibitors

JM Heuckmann, M Hölzel, ML Sos, S Heynck… - Clinical Cancer …, 2011 - AACR
Purpose: EML4–ALK fusions define a subset of lung cancers that can be effectively treated
with anaplastic lymphoma kinase (ALK) inhibitors. Unfortunately, the duration of response is …

A mouse model for EML4-ALK-positive lung cancer

M Soda, S Takada, K Takeuchi… - Proceedings of the …, 2008 - National Acad Sciences
EML4-ALK is a fusion-type protein tyrosine kinase that is generated in human non-small-cell
lung cancer (NSCLC) as a result of a recurrent chromosome inversion, inv (p21p23) …